Suramins and suradistas, an important group of potential anti-cancer agents, inhibit
fibroblast growth factor (FGF) mitogenic activity. It has been shown that …

Suramin, traditionally used in the treatment of trypanosomiasis, is under investigation in the
treatment of cancer. One side effect that limits its use is the onset of a sensorimotor …

Suramin is polysulfonated napthylurea which has a broad range of antitumor activity. The
mechanism of action of suramin is not completely understood, although it is known to inhibit …

Background: Previous studies indicate that suramin may be an active agent for treatment of
solid tumors. The clinical use of suramin is complicated by a broad spectrum of toxic effects …

We recently reported that acidic and basic fibroblast growth factors (aFGF and bFGF) confer
a broad-spectrum chemoresistance in solid tumors, and that inhibitors of these proteins …

Fifteen patients with advanced non small cell lung cancer (NSCLC) were entered into a
study of suramin given as a 4 h infusion of 350 mg/m 2 per day for 5 days, followed by 350 …

Purpose: Our preclinical studies have shown that acidic and basic fibroblastic growth factors
confer broad spectrum chemoresistance and that low concentrations (10–50 μm) of suramin …

Non‐small cell lung cancer (NSCLC) is fatal in approximately 90% of all cases due to the
failure of systemic therapy, secondary to resistance to chemotherapy. In such malignancies …

Purpose: Bioactive lipids have been causally linked to intraabdominal malignancies such as
ovarian cancer. In advanced tumors confined to the peritoneal cavity, inhibition of lipid …

Background Suramin has shown promising activity against prostate and breast cancer but is
severely neurotoxic. Complex adaptive pharmacokinetics have previously been used to …